$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000147929018000067 Filed on May 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$686.0K	$193.0K	$75.00K
YoY Change	814.67%	157.33%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.73M	$13.62M	$7.754M
YoY Change	47.91%	75.6%	4.01%
% of Gross Profit
Research & Development	$22.87M	$22.24M	$19.41M
YoY Change	24.93%	14.58%	56.98%
% of Gross Profit
Depreciation & Amortization	$420.0K	$390.0K	$357.0K
YoY Change	16.67%	9.24%	3.78%
% of Gross Profit
Operating Expenses	$35.61M	$35.86M	$27.16M
YoY Change	32.28%	32.0%	37.06%
Operating Profit	-$34.92M	-$35.66M	-$27.09M
YoY Change	30.1%	31.65%	37.2%
Interest Expense	$0.00	$44.00K	$193.0K
YoY Change	-100.0%	-77.2%	-38.73%
% of Operating Profit
Other Income/Expense, Net	-$172.0K	-$319.0K	-$126.0K
YoY Change	30.3%	153.17%	0.8%
Pretax Income	-$34.08M	-$35.04M	-$27.16M
YoY Change	26.83%	29.01%	36.55%
Income Tax
% Of Pretax Income
Net Earnings	-$34.08M	-$35.04M	-$27.16M
YoY Change	26.81%	29.02%	36.54%
Net Earnings / Revenue	-4967.93%	-18153.89%	-36208.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$925.1K	-$974.7K	-$942.7K
COMMON SHARES
Basic Shares Outstanding	36.78M shares	36.68M shares	29.32M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$233.7M	$268.8M	$188.6M
YoY Change	41.21%	42.52%	-20.29%
Cash & Equivalents	$39.28M	$69.21M	$38.24M
Short-Term Investments	$194.5M	$199.6M	$150.4M
Other Short-Term Assets	$9.100M	$4.600M	$8.800M
YoY Change	3.41%	-47.73%	363.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$242.9M	$273.4M	$197.5M
YoY Change	39.3%	38.47%	-17.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.20M	$10.06M	$11.21M
YoY Change	8.36%	-10.18%	-43.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.315M	$718.0K	$216.0K
YoY Change	273.31%	232.41%	0.0%
Total Long-Term Assets	$16.24M	$11.36M	$12.00M
YoY Change	27.65%	-5.32%	-41.49%
TOTAL ASSETS
Total Short-Term Assets	$242.9M	$273.4M	$197.5M
Total Long-Term Assets	$16.24M	$11.36M	$12.00M
Total Assets	$259.1M	$284.8M	$209.5M
YoY Change	38.51%	35.96%	-19.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.435M	$5.361M	$5.573M
YoY Change	33.24%	-3.8%	68.52%
Accrued Expenses	$13.57M	$11.12M	$14.97M
YoY Change	-5.42%	-25.7%	152.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.000M	$3.500M
YoY Change	-100.0%	-71.43%	6.06%
Total Short-Term Liabilities	$28.32M	$23.00M	$24.04M
YoY Change	28.89%	-4.35%	92.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.000M
YoY Change		-100.0%	-77.78%
Other Long-Term Liabilities	$20.90M	$25.10M	$100.0K
YoY Change		25000.0%	-98.08%
Total Long-Term Liabilities	$20.90M	$25.10M	$100.0K
YoY Change		25000.0%	-98.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.32M	$23.00M	$24.04M
Total Long-Term Liabilities	$20.90M	$25.10M	$100.0K
Total Liabilities	$49.27M	$48.14M	$30.78M
YoY Change	78.11%	56.38%	38.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$611.3M	-$577.2M	-$448.7M
YoY Change	28.53%	28.63%	27.42%
Common Stock	$821.4M	$814.1M	$627.5M
YoY Change	29.32%	29.74%	6.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$209.9M	$236.6M	$178.7M
YoY Change
Total Liabilities & Shareholders Equity	$259.1M	$284.8M	$209.5M
YoY Change	38.51%	35.96%	-19.13%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$34.08M	-$35.04M	-$27.16M
YoY Change	26.81%	29.02%	36.54%
Depreciation, Depletion And Amortization	$420.0K	$390.0K	$357.0K
YoY Change	16.67%	9.24%	3.78%
Cash From Operating Activities	-$36.56M	-$11.14M	-$21.19M
YoY Change	50.51%	-47.41%	35.15%
INVESTING ACTIVITIES
Capital Expenditures	-$1.270M	$1.068M	$296.0K
YoY Change	4.96%	260.81%	-57.1%
Acquisitions
YoY Change
Other Investing Activities	$5.100M	-$199.3M	-$28.28M
YoY Change	-86.51%	604.56%	-80.34%
Cash From Investing Activities	$3.830M	-$200.3M	-$28.57M
YoY Change	-89.53%	601.05%	-80.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$26.22M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.940M	-$2.222M	$25.00M
YoY Change	-6.96%	-108.89%	-4246.1%
NET CHANGE
Cash From Operating Activities	-36.56M	-$11.14M	-$21.19M
Cash From Investing Activities	3.830M	-$200.3M	-$28.57M
Cash From Financing Activities	2.940M	-$2.222M	$25.00M
Net Change In Cash	-29.79M	-$213.7M	-$24.77M
YoY Change	-292.69%	762.85%	-84.59%
FREE CASH FLOW
Cash From Operating Activities	-$36.56M	-$11.14M	-$21.19M
Capital Expenditures	-$1.270M	$1.068M	$296.0K
Free Cash Flow	-$35.29M	-$12.21M	-$21.49M
YoY Change	52.9%	-43.17%	31.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36783896	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
CY2018Q1	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2018Q1	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2017Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	1872000	USD
CY2018Q1	rvnc	Financing Obligation Current FinancingObligationCurrent	983000	USD
CY2017Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-60000	USD
CY2018Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-34000	USD
CY2018Q1	rvnc	Indemnification Liability IndemnificationLiability	0	USD
CY2017Q1	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2018Q1	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	16000	USD
CY2017Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-27156000	USD
CY2018Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-35037000	USD
CY2017	rvnc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	62900000	USD
CY2017	rvnc	Tax Cutsand Jobs Actof2017 Increase Decreaseto Valuation Allowance TaxCutsandJobsActof2017IncreaseDecreasetoValuationAllowance	-62900000	USD
CY2018Q1	rvnc	Working Capital Surplus WorkingCapitalSurplus	250400000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6805000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5361000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-194000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	255000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12225000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11120000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-276000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	810975000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	814084000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3155000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4158000	USD
CY2017Q4	us-gaap	Assets Assets	295699000	USD
CY2018Q1	us-gaap	Assets Assets	284780000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	285211000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	273418000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	236744000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	248690000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	276000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	236744000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	248966000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	282896000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69212000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	282900000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	268800000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64082000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39317000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69792000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24765000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-213684000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.95
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.95
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36516075	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36742847	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36516075	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36742847	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27208000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35313000	USD
CY2017Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	78000	USD
CY2018Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	109000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3339000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3221000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5532000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	19275000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	44000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	24807000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-69000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-290000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1144000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2310000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	193000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	357000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	390000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2613000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2647000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2017Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	83000	USD
CY2018Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	44000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1135000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1269000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2055000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1980000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	16000	USD
CY2017Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	311000	USD
CY2018Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1022000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2017Q4	us-gaap	Liabilities Liabilities	26854000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	48139000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295699000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284780000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20902000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22996000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25001000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2222000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28574000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200318000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21192000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11100000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11144000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-27156000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-35000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-35037000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	882000	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	839000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	27163000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	35855000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27088000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-35662000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	36719000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6173000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5996000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5812000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	14512000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4226000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2018Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	658000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	718000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-52000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-276000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-126000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-319000	USD
CY2017Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	205000	USD
CY2018Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	241000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	277000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1666000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	36028000	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	199265000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	296000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1068000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2315000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4612000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26217000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	7750000	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	210000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	617000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9250000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10064000	USD
CY2018Q1	us-gaap	Purchase Obligation PurchaseObligation	1300000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	944000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	932000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19409000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22239000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-542167000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577204000	USD
CY2018Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	200000	USD
CY2017Q1	us-gaap	Revenues Revenues	75000	USD
CY2018Q1	us-gaap	Revenues Revenues	193000	USD
CY2017Q4	us-gaap	Royalty Revenue RoyaltyRevenue	75000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7754000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13616000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3155000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4158000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	199594000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	268845000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	236641000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28808195	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35950593	shares
CY2018Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company entered into a license agreement with Medicis Pharmaceutical Corporation, or Medicis, granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidates. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) a Product Approval Payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">2.25</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">2.30%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, accruals, stock-based compensation, the fair value of a derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-18-000067-index-headers.html	Edgar Link	pending
0001479290-18-000067-index.html	Edgar Link	pending
0001479290-18-000067.txt	Edgar Link	pending
0001479290-18-000067-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20180331.xml	Edgar Link	completed
rvnc-20180331.xsd	Edgar Link	pending
rvnc-20180331_cal.xml	Edgar Link	unprocessable
rvnc-20180331_def.xml	Edgar Link	unprocessable
rvnc-20180331_lab.xml	Edgar Link	unprocessable
rvnc-20180331_pre.xml	Edgar Link	unprocessable
rvnc-q118exhibit101.htm	Edgar Link	pending
rvnc-q118exhibit311.htm	Edgar Link	pending
rvnc-q118exhibit312.htm	Edgar Link	pending
rvnc-q118exhibit321.htm	Edgar Link	pending
rvnc-q118exhibit322.htm	Edgar Link	pending
rvncq11810q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2018 Q2 Form 10-Q Financial Statement

#000147929018000067 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2018 Q2 Form 10-Q Financial Statement

#000147929018000067 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc